MDM2 and non-small cell lung carcinoma: To further validate that MDM2 is a candidate target for wtTP53‐RTK NSCLC, we implanted NCI‐H460 MDM2 WT (control) and KO cells in NCG immunodeficient to evaluate their tumourigenicity in the xenograft model.